The first people' s hospital of lanzhou city, Lanzhou, 730000, China.
BMC Neurol. 2022 Sep 13;22(1):345. doi: 10.1186/s12883-022-02875-z.
In order to promote the clinical translation of preclinical findings, it is imperative to identify the most optimal therapeutic conditions and adopt them for further animal and human studies. This study aimed to fully explore the optimal conditions for neural stem cell (NSC)-based ischemic stroke treatment based on animal studies.
The PubMed, Ovid-Embase, and Web of Science databases were searched in December 2021. The screening of search results, extraction of relevant data, and evaluation of study quality were performed independently by two reviewers.
In total, 52 studies were included for data analysis. Traditional meta-analysis showed that NSCs significantly reduced the modified neurological severity score (mNSS) and volume of cerebral infarct in animal models of ischemic stroke. Network meta-analysis showed that allogeneic embryonic tissue was the best source of NSCs. Further, intracerebral transplantation was the most optimal route of NSC transplantation, and the acute phase was the most suitable stage for intervention. The optimal number of NSCs for transplantation was 1-5×10 in mouse models and 1×10 or 1.8×10 in rat models.
We systematically explored the therapeutic strategy of NSCs in ischemic stroke, but additional research is required to develop optimal therapeutic strategies based on NSCs. Moreover, it is necessary to further improve and standardize the design, implementation, measuring standards, and reporting of animal-based studies to promote the development of better animal experiments and clinical research.
为了促进临床前研究结果的临床转化,确定最佳的治疗条件并将其应用于进一步的动物和人体研究至关重要。本研究旨在通过动物研究充分探索基于神经干细胞(NSC)的缺血性脑卒中治疗的最佳条件。
于 2021 年 12 月检索 PubMed、Ovid-Embase 和 Web of Science 数据库。由两位评审员独立进行检索结果筛选、相关数据提取和研究质量评估。
共纳入 52 项研究进行数据分析。传统荟萃分析显示,NSC 可显著降低缺血性脑卒中动物模型的改良神经功能缺损评分(mNSS)和脑梗死体积。网络荟萃分析显示,异体胚胎组织是 NSCs 的最佳来源。此外,脑内移植是 NSC 移植最优化的途径,干预的最适阶段为急性期。在小鼠模型中,最佳移植 NSC 数量为 1-5×10,在大鼠模型中为 1×10 或 1.8×10。
我们系统地探讨了 NSCs 在缺血性脑卒中治疗中的策略,但需要进一步研究以制定基于 NSCs 的最佳治疗策略。此外,有必要进一步改进和规范基于动物的研究的设计、实施、测量标准和报告,以促进更好的动物实验和临床研究的发展。